..
..
Innovative study uncovers new treatment approach reducing cervical cancer rates
By Blaine Ainsley
50 minutes ago
A ground-breaking research project led by UCL, funded by Cancer Research UK, discovers a potential 35% reduction in cervical cancer death and recurrence rates using an innovative combination of existing chemotherapy drugs. This affordable and effective new approach may represent a significant advancement in cervical cancer treatment.
Stunning strides are being made in the fight against cervical cancer, thanks to an innovative study conducted by a dedicated team of researchers. The study, centred around a new use for existing drugs, discovered a potential 35% reduction in both death and recurrence rates of cervical cancer patients. This is achieved by a short course of induction chemotherapy (IC) before the traditional chemoradiation (CRT) method of treatment.
This potentially life-saving research was carried out at renowned institutions, UCL Cancer Institute and UCLH, and funded by Cancer Research UK. The research cohort included 500 patients drawn globally from the UK, Mexico, India, Italy, and Brazil.
The results are eye-opening. After a 5-year span, a notable 80% of patients who received IC integrated with CRT were still alive, compared with 72% survival for patients having undergone only standard CRT treatment. Further, 73% of the experimental group presenting no signs of cancer recurrence or spread, compared to 64% of the conventional treatment group.
Dr Mary McCormack, heading the investigative team, dubbed these findings as the “biggest improvement in outcome in this disease in over 20 years”. Such a groundbreaking discovery is a beacon of hope for the approximately 3,200 women diagnosed with cervical cancer in the UK every year, most in their early 30s.
The winning feature of this new approach is the use of approved and inexpensive induction chemotherapy drugs, namely carboplatin and paclitaxel. The benefits of their affordability and accessibility, combined with their demonstrated effectiveness, suggest a real possibility of rapid integration into standard care treatment. Given the potential in these findings, the fight to save women’s lives from cervical cancer just got a potent new weapon.
..
weehingthong 